Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07675824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Study acronym: BAHAMA
StatusRecruiting
PhasePhase 1/2
Started2026-09-08
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 51 days later Jul 25, 2029 → Sep 14, 2029
See other at-risk trials from Regeneron

Amendment history

2026-09-29
Recruitment opened
Primary completion pushed: 2029-07-25 → 2029-09-14
Completion pushed: 2029-10-16 → 2029-12-06
Regeneron
148 trials monitored
See 16 trials at risk
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP). REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure. The study is looking at: * What side effects REGN22530 might cause * How much REGN22530 is in the blood and eye fluid at different times * If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well) * How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others * How well REGN22530 works
Trial Details
NCT Number NCT07675824
Lead Sponsor Regeneron Pharmaceuticals
Conditions Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Enrollment 271 participants
Start Date 2026-09-08
Primary Completion 2029-09-14 (estimated)
Study Completion 2029-12-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-28